Latest News and Press Releases
Want to stay updated on the latest news?
-
TEL-AVIV, Israel, May 27, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"), an Israeli biopharmaceutical company primarily focused on late clinical-stage,...
-
RedHill's Investor Webcast Forum, held on May 14, 2015, focused on the development program for RHB-105, currently undergoing a first Phase III study (ERADICATE Hp study) for the treatment of H....
-
TEL-AVIV, Israel, May 8, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary,...
-
RedHill will host an interactive investor forum on H. pylori bacterial infection and RHB-105, on Thursday, May 14, 2015, at 8:00-9:30 am Eastern Time. Participants are invited to join the forum...
-
TEL-AVIV, Israel, May 4, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
-
Key Highlights Include: Strong cash position of approximately $32.5 million at the end of the first quarter of 2015, following the closing of the Company's first public offering in the U.S....
-
TEL-AVIV, Israel, April 28, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE: RDHL) ("RedHill"), an Israeli biopharmaceutical company primarily focused on late clinical-stage,...
-
The last patient has been enrolled in the ERADICATE Hp study - a randomized, placebo-controlled, first Phase III study evaluating RHB-105 as a first-line therapy for H. pylori bacterial...
-
TEL-AVIV, Israel, April 21, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
-
The U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a new formulation patent application covering RHB-105 H. pylori bacterial infection treatment, to expire no...